The center brings together faculty investigators and other personnel with a mission to study the molecular basis of human disease and its treatment as they relate to genomic variation, leading to personalized medicine. These endeavors utilize genomic information from patients and/or experimental systems. The goals of such investigations are to harness genomic information and its variation in humans or experimental systems to: 1) devise methods to tailor medical care for prediction of disease rise, prognosis, and treatment and 2) to identify novel pathways relevant to mechanism of disease and drug targets.
Described herein are let-7f miRNA inhibitors and uses thereof. In some embodiments, the let-7f miRNA inhibitors can be capable of reducing method of reducing ??-agonistmediated ??2-Adrenergic Receptor (??2AR) down regulation in a subject in need thereof.We have developed a method to significantly limit beta2-andrenergic receptor downregulation. By inhibiting a specific transcription factor, the upregulation of various microRNA are also inhibited, which then limits the microRNA’s ability to downregulate the beta2-andrenergic receptors. When treated by the aforementioned method, a significant decrease was found in beta2-andrenergic receptor downregulation in cultured human airway smooth muscle (HASM) cells. This novel method may provide a means to maintain the effectiveness of beta-agonist based treatments for pulmonary disorders.